-
Views
-
Cite
Cite
R. Asmar, P. Gosse, J. Topouchian, N'tela, S. Gray, A. Dudley, P-254: Effects of telmisartan on arterial compliance and endothelial function in type 2 diabetes patients with essential hypertension, American Journal of Hypertension, Volume 14, Issue S1, April 2001, Page 114A, https://doi.org/10.1016/S0895-7061(01)02108-2
Close - Share Icon Share
Abstract
The effects of telmisartan on arterial compliance and endothelial function in subjects with type 2 diabetes suffering from light to moderate essential hypertension were investigated (protocol AZA30003). Twenty patients were randomised into a double-blind, placebo-controlled, 3 week cross-over study to receive either telmisartan (40 mg) or placebo after a 2 week placebo run-in period. The primary endpoint was the effect of telmisartan on arterial distensibility as measured by pulse wave velocity (carotid-femoral route) compared with placebo. Secondary endpoints included the effects of telmisartan on pulse wave velocity (carotid radial route) and further pulse wave analysis including measurements of augmentation index, ejection duration, first and second peak delays, subendocardial viability, brachial and central blood pressures. Insulin resistance and markers of endothelial function were also measured. Telmisartan significantly reduced the pulse wave velocity by the carotid femoral route. The mean adjusted treatment difference was –0.95 m/s (95% confidence intervals: -1.67, -0.23 m/s, p=0.013) in favour of telmisartan. The results of the peripheral and DBP, SBP and pulse pressure were highly significant in favour of telmisartan compared with placebo. Details of these results and those of other secondary analyses will be presented at the meeting. Such findings show that telmisartan is effective at reducing arterial stiffness in hypertensive patients with type 2 diabetes mellitus.
